Browse the evidence

Weight loss was consistently larger in the incretin intervention groups than in placebo or lifestyle intervention comparators.

Incretin therapies may be more effective for weight loss compared to lifestyle changes or placebo.

Semaglutide initiated 6 months post LSG results in significantly greater absolute weight loss of 14.03 ± 5.26 kg compared to 5.63 ± 6.25 kg in controls from 6 to 12 months post LSG (p < 0.0001).

Practitioners may consider semaglutide as an effective adjunct therapy for weight management in patients post-sleeve gastrectomy.

Semaglutide therapy leads to a higher percentage weight loss of 12.61% ± 4.11% compared to 4.84% ± 5.18% in controls from 6 to 12 months post LSG (p < 0.0001).

Semaglutide may be recommended for patients post-surgery to enhance weight loss outcomes.

At 12 months, total weight loss was higher in the treatment group (35.77% ± 8.35%) compared to controls (28.37% ± 7.41%; p < 0.0001).

The findings support the use of semaglutide for improved long-term weight management post-surgery.

Patients with a longer duration of GLP-1RA treatment are more likely to achieve successful weight reduction at follow-up of 12 months (OR = 1.014).

Practitioners should consider the duration of GLP-1RA treatment as a factor in achieving weight loss.

Using semaglutide is associated with successful weight reduction at the follow-up of 6 months (OR = 2.138).

Semaglutide may be a more effective option for weight reduction in patients treated with GLP-1RA.

Weight loss significantly explained heterogeneity in treatment effects on fibrosis improvement and MASH resolution.

Weight management should be emphasized in treatment plans for MASH to enhance treatment efficacy.

GLP-1 receptor agonist treatment is associated with a 10.3% reduction in fat mass (FM) at 6 months, 17.3% at 12 months, and 18.0% at 24 months.

GLP-1RA treatment leads to significant fat mass reduction over 24 months.

GLP-1 receptor agonists produced greater weight loss among women (10.9%; 95% CI, 7.0%-14.8%) than men (6.8%; 95% CI, 4.6%-9.0%).

Practitioners should consider gender differences when prescribing GLP-1 receptor agonists for weight loss.

The combination of Cinnamomum cassia (300 mg) and Withania somnifera (150 mg) induced significant weight loss compared to placebo (−2.66% vs. −1.28%, respectively; p = 0.0002).

Practitioners may consider this combination as a low-cost supplement option for enhancing weight loss in overweight and obese patients.

The study suggests that the combination of CC and WS may enhance weight loss in patients on a mildly hypocaloric diet.

This combination may be recommended as a supplement to support weight loss efforts in conjunction with dietary changes.

Obesity is associated with serious health risks and consequences for individuals who are pregnant or want to be pregnant.

Healthcare providers should be aware of the risks obesity poses to pregnant individuals.

GLP-1-based medications can achieve up to 24% weight loss, aiding in the effective management of obesity and its complications.

Practitioners can consider GLP-1 medications as a viable option for weight management in obese patients.

Semaglutide, a GLP-1 receptor agonist, can lead to weight reductions of up to 15%.

Practitioners should consider the potential effectiveness of semaglutide for weight loss in patients.

Lifestyle interventions, such as adherence to a Mediterranean diet and weight loss, have proven beneficial for both metabolic dysfunction-associated steatotic liver disease (MASLD) and heart failure with preserved ejection fraction (HFpEF).

Encouraging patients to adopt a Mediterranean diet and focus on weight loss can be beneficial for managing both MASLD and HFpEF.

Incretin-based therapies induced substantial weight loss, mostly from fat mass.

Practitioners can consider incretin-based therapies as effective options for promoting fat loss in T2D patients.

Broad access to semaglutide would result in 38,950 cardiovascular events avoided and 6,180 deaths avoided over a 10-year period.

Practitioners should consider the significant health benefits of prescribing semaglutide to eligible Medicare patients.

A significantly higher rate of patients from the pure Semaglutide group achieved the ten percent (50.54% vs. 44.64%) and fifteen percent (21.42% vs. 12.78%) weight loss thresholds compared to the compounded Semaglutide group.

Practitioners should note that pure Semaglutide may lead to better outcomes in achieving significant weight loss thresholds.

Lifestyle interventions that include diet, exercise, and behavioral modification have been the foundation for management of obesity.

Practitioners should prioritize lifestyle interventions in obesity treatment plans.

The American Gastroenterological Association recommended adding pharmacologic agents to lifestyle interventions for adults with obesity or overweight with weight-related complications who have had an inadequate response to lifestyle interventions alone.

Practitioners should consider pharmacologic options for patients not responding to lifestyle changes.

Incretin analogs (liraglutide, semaglutide, and tirzepatide) are effective for weight management in adults without diabetes, with percent weight loss ranging from 5.7% to 20.9%.

Healthcare providers can consider prescribing these agents for weight management in overweight or obese patients without diabetes.

GLP-1 receptor agonists provide glycemic and complication-risk reduction benefits for individuals with type 2 diabetes.

Practitioners can consider GLP-1 receptor agonists as effective treatment options for managing glycemic levels and reducing complications in type 2 diabetes patients.

Semaglutide leads to significantly higher overall weight loss compared to placebo and most other comparison treatments.

Semaglutide may be a viable option for practitioners looking to support weight loss in obese and overweight patients.

CagriSema is being marketed as a safe and potentially superior medication to lower both Hemoglobin A1c and body weight.

Practitioners may consider CagriSema as a treatment option for patients needing glycemic control and weight management.